Immunotherapy Using Autologous T Cell-Engineered With CD19-specific Chimeric Antigen Receptor for the Treatment of Recurrent /Refractory B Cell Leukemia
Clinical trial NCT02644655 · UNKNOWN
Trial details
- NCT number
- NCT02644655
- Sponsor
- Second Military Medical University
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-09-01
- Primary completion
- 2017-03-01
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.